F8 and hemophilia A: Published findings from the XTEND‐1 trial in adults and adolescents with severe hemophilia A showed that efanesoctocog alfa had a geometric mean half‐life of 47.0 h (95% confidence interval, 42.3–52.2) and maintained FVIII levels in the normal to near‐normal range of > 40% for 4 days and 15% by the end of the week [19].